WHO HVAC Guidelines for Pharmaceutical Manufacturing
A practical guide to WHO expectations for pharmaceutical HVAC design, contamination control, pressure cascades, qualification, monitoring and lifecycle maintenance.
Heating, ventilation and air conditioning (HVAC) is a GMP utility that shapes the manufacturing environment. In a pharmaceutical plant, it does more than cool or heat rooms: it supplies and removes air, limits ingress of contaminants, helps manage dust and product cross-contamination, and maintains conditions required by products, processes, equipment and personnel.
The World Health Organization’s HVAC guidance is risk-based rather than a single table of fixed values for every facility. WHO TRS 1010, Annex 8 (2018) gives detailed GMP recommendations for HVAC systems used in non-sterile pharmaceutical manufacturing. Its companion TRS 1019, Annex 2 (2019), provides interpretive examples and is described as non-binding. For sterile manufacturing, use WHO TRS 1044, Annex 2 (2022), which contains separate requirements for sterile-product premises and cleanroom qualification. This distinction matters: a non-sterile HVAC design guide is not a substitute for sterile-product requirements.
For foundational context, see our guides to cGMP and HVAC validation in pharmaceuticals.
Which WHO HVAC Guideline Applies?
| WHO document | Primary scope | How to use it |
|---|---|---|
| TRS 1010, Annex 8 (2018) | GMP HVAC design, qualification, management and maintenance for non-sterile pharmaceutical products | Primary detailed HVAC guide for non-sterile facilities; read with WHO GMP main principles and relevant product-specific guidance. |
| TRS 1019, Annex 2 (2019) | Interpretation of the non-sterile HVAC guide | Provides explanatory drawings and examples; WHO describes it as non-binding and not prescriptive in setting design parameters. |
| TRS 1044, Annex 2 (2022) | GMP for sterile pharmaceutical products | Use for sterile cleanrooms, contamination control, cleanroom grades, airflow protection, qualification and monitoring. |
WHO TRS 1010 notes that some general HVAC principles can be considered for other dosage forms, API finishing steps and facilities, but additional requirements may apply to hazardous, sterile and biological products. Determine the applicable guidance before fixing the design basis.
Objectives of Pharmaceutical HVAC
A fit-for-purpose HVAC system should maintain conditions that protect the product and process without creating new risks. WHO guidance identifies several connected objectives:
Protect product quality
Maintain suitable air cleanliness, temperature, humidity and airflow for the materials and process, including exposed product and packaging components.
Prevent cross-contamination
Control dust migration, air movement between rooms, recirculated air, return-air paths and shared equipment or ducting risks.
Protect operators
Provide appropriate containment and local extraction for dusty or hazardous operations, based on occupational and product risks.
Protect the environment
Assess exhaust streams and install suitable filtration or other control technology where emissions may contain dust or contaminants.
These goals can compete. For example, a room may need to protect exposed product from external contamination while also containing a potent powder. The pressure cascade and air-handling strategy should therefore be developed through risk assessment, not copied from another suite.
Risk-Based HVAC Design and Contamination Control
WHO recommends applying risk management throughout the HVAC lifecycle. Start with product and process knowledge: dosage form, dustiness, sensitizing or potent properties, solvent use, microbial susceptibility, exposure of materials, equipment heat loads, room occupancy and cleaning practices. Consider failure modes for fans, filters, coils, sensors, dampers, controls and dust-extraction equipment.
Use the assessment to select the system architecture and define critical parameters. Typical parameters include supply, return and exhaust air quantities; room pressure differences; airflow direction; temperature and relative humidity; filter performance; room air-change rate where used; and local capture velocity for containment systems.
Premises, Room Layout and Airlocks
HVAC and building layout should be planned together from the early design stage. Doorways, corridors, airlocks, pass-through hatches, equipment placement and personnel/material flows can affect room pressure and contamination risks. The building should be designed to prevent unfiltered air infiltration, and diagrams should show supply, return and exhaust paths, room pressure differences and intended airflow directions.
For many non-sterile manufacturing areas, maintaining positive pressure relative to the outside helps reduce ingress of contaminants. Negative pressure may be necessary for containment; if so, specific controls should manage both inward and outward contamination risks. In dusty multiproduct operations, the pressure cascade may be arranged to contain dust at the source. The appropriate direction depends on what is being protected and from what.
Airlocks and change rooms can support segregation, but their doors, use and pressure relationship must fit actual workflows. Assess movement of people, materials, waste and equipment through each boundary. The cleanroom classification or cleanliness level should be defined based on products, process and susceptibility to degradation.
Air Handling Units, Fresh Air and Recirculation
Air-handling unit design
AHUs should have enough capacity to maintain required performance during normal operating conditions, accounting for room and duct leakage, filter loading and operational demand. Component materials should not become contamination sources. Intake and exhaust terminals should be positioned to reduce the risk of exhaust re-entering the building. The design should address condensate drainage, access for cleaning and maintenance, and clear identification of ductwork, sensors and flow direction.
Full fresh air or recirculated air
WHO permits either full-fresh-air or recirculation systems for non-sterile products when the selected approach is supported by risk assessment. Fresh air must be adequately filtered. A recirculation system must not create contamination or cross-contamination risk. Air that may contain organic solvents or highly hazardous materials should normally not be recirculated.
HEPA filtration may be installed in supply or return air to reduce contaminants and prevent cross-contamination. Where used for this purpose, WHO specifies at least EN 1822 H13 or equivalent. WHO also explains that HEPA filters may not be needed for this particular cross-contamination control when robust alternative technical controls demonstrate no risk, or where the HVAC system serves a single-product facility. This does not remove any separate filter requirement arising from cleanroom classification, sterile manufacturing or another applicable standard.
Exhaust and dust extraction
HVAC should not normally be the primary dust-control mechanism. Capture dust close to the source with an appropriately designed extraction system. Prevent dust from flowing backward during fan or airflow failure, avoid settling in ducts, and assess interlocks between dust extraction and the relevant AHU. Exhaust filtration and waste handling should be based on the contaminant and environmental risk.
Airflow Direction and Pressure Differentials
WHO expects airflow direction and pressure differences to be selected for the products handled and the protection needed for product, operator and environment. In a typical dusty process, a pressure cascade may direct air from a cleaner corridor toward a dust-generating room to contain powder. A different arrangement may be required for a product-exposure or containment hazard. Set limits so the normal dynamic operating ranges do not overlap and the intended direction remains reliable during routine operations.
Provide pressure indication through suitable gauges or electronic monitoring. Define normal ranges, alert limits and action limits, and display them at the point of indication or in the EMS/BMS. Calibrate monitoring devices and periodically verify the cascade across connected rooms. Account for transient conditions such as doors opening, local exhaust operation and production equipment cycling.
Use alarms for critical component failure or out-of-limit conditions. Written procedures should tell personnel what to do, including whether production must stop, what happens to exposed materials, who reviews potential impact and how the event is documented. GxP-relevant automated monitoring and control systems should be appropriately validated; see Computerized System Validation.
Temperature, Relative Humidity and Air Changes
Temperature and relative-humidity limits should be specified when needed to protect product, materials, process performance, equipment or personnel. Consider hygroscopic powders, moisture-sensitive products, static electricity, condensation, drying operations and operator comfort. Monitoring locations and alert/action limits should reflect the room's risks and known gradients.
Air-change rates and airflow quantities should likewise be justified by room performance rather than chosen as unsupported rules of thumb. WHO lists room air-change rate among parameters that may be controlled and included in HVAC qualification where relevant. Demonstrate that the selected airflow achieves the required room flushing, contamination control and recovery performance.
Commissioning, Qualification and Validation
WHO describes commissioning as a precursor to qualification. Commissioning confirms that installed equipment and controls operate as intended under good engineering practice; qualification provides documented evidence that the HVAC system performs consistently against approved GMP requirements. A risk-based scope should be described in the validation or qualification master plan.
Use a lifecycle approach that connects requirements to design, installation, operation and performance. Prepare a URS, approve design requirements and risk controls, then document the relevant DQ, IQ, OQ and PQ activities as applicable. The specific labels may vary by site, but traceability and evidence should remain clear.
| Qualification activity | Typical HVAC evidence |
|---|---|
| Design review / DQ | Approved design basis, room classification or cleanliness rationale, pressure cascade, airflow scheme, equipment capacity, filter strategy and risk controls. |
| Installation / IQ | AHU and component identification, drawings, filter certificates, ductwork and damper installation, instruments, utilities and calibration status. |
| Operational / OQ | Control sequences, operating ranges, alarms/interlocks, pressure indication, failure response, start/stop logic and functional challenges. |
| Performance / PQ | Air quantities, room pressures, airflow direction, temperature/RH, particle or microbial data where applicable, recovery and operational performance. |
The approved protocol should define the scope, test methods, sampling points, instruments, calibration, acceptance criteria, responsibilities, deviation handling and report requirements before execution. Relevant test parameters may include supply/return/exhaust quantity, room air-change rate, room pressure, airflow pattern, velocity, HEPA penetration, particle count, duct leakage, microbial counts, dust extraction and room recovery. Not every test applies to every system; document the rationale.
Routine Monitoring, Maintenance and Requalification
Qualification is not a one-time certificate. WHO expects performance monitoring and records to show continued compliance with defined limits. Trend alarms, room pressure, temperature and humidity, filter differential pressure, air quantities and other critical parameters at a frequency suited to their risk and control strategy. Investigate adverse trends before they become excursions.
Provide procedures for AHU start-up and shutdown. WHO advises avoiding routine shutdown or reduced air volumes during non-production periods where this could compromise product or materials. If shutdown is proposed, justify it, demonstrate acceptability and document the procedure. Planned preventive maintenance should match component criticality, and maintenance should not adversely affect product quality.
Requalification frequency should be established based on risk, facility type, product protection needs, observed performance and ongoing monitoring. Changes to filters, fan capacity, controls, room layout, production equipment or pressure set points should pass through change control; determine the required testing from the change's impact. Use deviations and CAPA when performance failures or recurring events reveal a system weakness.
WHO HVAC GMP Documentation Checklist
- HVAC system description, design basis and risk assessment.
- Current as-built drawings for AHUs, supply, return, exhaust and ductwork.
- Room cleanliness or classification rationale, intended state and room-use map.
- Pressure cascade diagram, normal ranges, alert/action limits and monitoring points.
- Filter specifications, installation records, test results and replacement history.
- Approved commissioning and qualification plan, protocols, raw data and reports.
- Alarm, interlock, shutdown and failure-response procedures with challenge evidence.
- Temperature, humidity, air quantity and other routine monitoring trends.
- Preventive maintenance, calibration, repairs and component-change records.
- Change-control assessments and documented decisions on requalification scope.
- Validated status and access controls for GxP-relevant EMS/BMS functions.
Controlled SOPs should define operation, monitoring, alarm response, maintenance, change control and shutdown/start-up. Maintain attributable, legible and traceable electronic and paper records in line with ALCOA+ data-integrity principles.
Common HVAC Compliance Gaps
- Copying an air-change rate, pressure value or temperature range from another facility without site-specific rationale.
- Using positive pressure everywhere even when containment requires a different approach.
- Recirculating solvent-laden or highly hazardous air without an adequate risk assessment.
- Relying on room HVAC to capture powder instead of providing effective source extraction.
- Allowing pressure-monitoring gauges or sensors to remain uncalibrated or unreadable.
- Failing to document alarm response, fan failure consequences or AHU shutdown conditions.
- Keeping outdated as-built drawings after renovations or equipment changes.
- Using a qualification report without maintaining a continuing monitoring and preventive-maintenance program.
Quick WHO HVAC Audit Checklist
- Is the applicable WHO guide identified for the product type, including separate sterile or hazardous-substance requirements where relevant?
- Are HVAC limits tied to product, process, operator and environmental risks?
- Do current drawings accurately show airflow, pressure relationships and exhaust paths?
- Are fresh-air filtration and recirculation decisions justified and controlled?
- Are critical room pressures, alarms, action limits and response procedures established?
- Are dust extraction and HVAC interlocks qualified where needed?
- Does the qualification master plan justify test scope and acceptance criteria?
- Are change controls linked to impact assessment and requalification decisions?
- Are BMS/EMS functions that affect GxP decisions validated and their records protected?
Key Takeaways
- WHO TRS 1010 Annex 8 is the primary detailed HVAC GMP reference for non-sterile pharmaceutical products.
- TRS 1019 Annex 2 provides interpretive support; it is non-binding. Sterile facilities should follow the distinct sterile GMP guidance, TRS 1044 Annex 2.
- HVAC design should prevent contamination and cross-contamination while protecting products, operators and the environment.
- Pressure, filtration, recirculation and environmental limits must be chosen for the actual process, not copied as universal values.
- Commissioning, risk-based qualification, monitoring, preventive maintenance and change control keep the system in a controlled state.
Frequently Asked Questions
Which WHO guideline covers HVAC in pharmaceutical manufacturing?
WHO TRS 1010, Annex 8 (2018) covers GMP HVAC systems for non-sterile pharmaceutical products. TRS 1044, Annex 2 (2022) covers sterile-product GMP, including cleanroom and clean-air-equipment qualification. TRS 1019, Annex 2 (2019) is an interpretive companion for the non-sterile HVAC guideline.
Does WHO prescribe one fixed air-change rate for every pharmaceutical room?
No. The facility should establish airflow and air-change requirements from the intended room conditions, process risks and demonstrated system performance. The limits and rationale should be documented and qualified.
Are HEPA filters mandatory in every non-sterile pharmaceutical HVAC system?
Not necessarily. WHO says HEPA filters may be used in supply or return air to control cross-contamination; it describes circumstances where other robust technical controls or a single-product facility may make HEPA unnecessary for that specific purpose. Other standards or sterile/cleanroom requirements may still require them.
Can pharmaceutical HVAC air be recirculated?
WHO allows fresh-air or recirculation systems if the design does not create contamination or cross-contamination risk. Air that may be contaminated with organic solvents or highly hazardous materials should normally not be recirculated.
What is the purpose of a pharmaceutical pressure cascade?
A pressure cascade establishes the intended direction of air movement between rooms. Depending on the risk, it can help protect exposed product from less-clean surroundings or contain dust and hazardous materials. Its direction and limits must reflect the specific process and protection strategy.
Does WHO require HVAC qualification?
Yes. WHO TRS 1010 Annex 8 calls for HVAC systems to be qualified to demonstrate continued performance against specifications. Qualification scope should be risk-based and described in a master plan.
How often should HVAC systems be requalified?
WHO TRS 1010 Annex 8 does not give one universal time interval. A site should set frequency based on risk, facility type, product-protection needs, system performance and ongoing monitoring. Changes should be assessed through change control to decide the requalification scope.
Are WHO sterile HVAC requirements the same as non-sterile requirements?
No. WHO publishes separate sterile-product GMP guidance. Sterile cleanroom classification, contamination control and clean-air qualification requirements should be taken from the applicable sterile guidance rather than inferred from the non-sterile HVAC guide.
Conclusion
WHO HVAC guidelines call for a system that is designed around the process, qualified against approved requirements, monitored in routine operation and maintained throughout its lifecycle. The strongest programs make the rationale visible: why each pressure relationship, filter, airflow path, environmental range and alarm exists, and how the site knows the control remains effective. Use the correct WHO document for sterile or non-sterile operations, document risk-based decisions, and connect HVAC records to the pharmaceutical quality system.
Official WHO References
- WHO TRS 1010, Annex 8 (2018): Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products.
- WHO TRS 1019, Annex 2 (2019): Interpretation of guidelines on HVAC systems for non-sterile pharmaceutical products.
- WHO TRS 1044, Annex 2 (2022): WHO good manufacturing practices for sterile pharmaceutical products.
- WHO guidelines for pharmaceutical production.
Editorial note: This article is an educational overview, not a substitute for the current official WHO publications, national GMP requirements, site-specific engineering assessment or quality-unit approval.
.webp)
